



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54235

**Title:** Non-invasive prediction of persistent villous atrophy in celiac disease

**Reviewer’s code:** 00029962

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Full Professor

**Reviewer’s Country/Territory:** Italy

**Author’s Country/Territory:** Czech Republic

**Manuscript submission date:** 2020-01-16

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-01-17 14:22

**Reviewer performed review:** 2020-01-17 14:58

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

In this retrospective study, the Authors investigate the accuracy of different non-invasive tools (antibodies, ultrasonography, symptoms) to assess the persistence of villous atrophy (VA) in Celiac Disease patients (CD). They have shown that none of the above tools per se is sufficiently accurate to predict VA persistence as desirable in clinical practice, but the combination of serology and US can increase the overall accuracy. The study is interesting yet shows some major flaws: 1. Why only 82/190 patients had available biopsies? If the clinical pattern of patients was ruling the decision to go for as biopsy, you may have selected patients with a more severe disease and hence more prone to show persistent atrophy 2. What is the need to show persistent atrophy beyond clinical or laboratory response? Your data do not seem to support this need. Please expand 3. Results : "Autoantibodies aTTG were positive (cut-off value 18U/ml recommended by manufacturer) in 18 cases (22,2%), aDGP were positive (cut-off value 20U/ml determined by laboratory) in 29 cases (37,2%)." Was this observed at diagnosis, at follow-up? If at FU, the high proportion of positive antibodies may show inadequate adherence to GFD or refractory disease 4. Is US a validated technique for the diagnosis and follow-up of CD patients? Not to the best of my knowledge. Please expand or take out 5. Data should be either in the text or in tables 6. A calculation of the sample needed to reach statistical significance should be given



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54235

**Title:** Non-invasive prediction of persistent villous atrophy in celiac disease

**Reviewer's code:** 00039368

**Position:** Editorial Board

**Academic degree:** DA, PhD

**Professional title:** Academic Research

**Reviewer's Country/Territory:** Estonia

**Author's Country/Territory:** Czech Republic

**Manuscript submission date:** 2020-01-16

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-03-26 08:24

**Reviewer performed review:** 2020-03-27 11:23

**Review time:** 1 Day and 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

This clinical study considers the evaluation of possible predictor factors of villous atrophy in celiac disease, like anti-tissue transglutaminase antibodies, anti-deamidated gliadin peptide antibodies, and abdominal ultrasonography. This study makes an additional contribution to studies which help to improve non invasive diagnostic possibilities and find reliable widely available non-invasive marker of persistent villous atrophy (VA), in celiac disease patients. The study is set up correctly. The material studied allows to draw the conclusions. The paper is written well, the Introduction give a good overview about the study background and the authors raised clearly the hypothesis of the study. The description of material studied is accurate. The aim of the study is fulfilled. The material studied is large enough and allows to draw the conclusions. The Results are presented clearly and have been discussed well. The 7 tables give good overview about the results. The authors find that a combination of serology with ultrasound imaging increased positive predictive value and specificity to 88.9% and 98% for aTTG IgA and to 90.0% and 97,8% for aDGP IgA to predict persistent atrophy. The combination of serology and experienced bowel ultrasound examination may achieve better accuracy in the detection of atrophy. Asymptomatic patients with lower levels, particularly of both aDGP IgA and IgG, do not need to undergo the follow-up duodenal biopsy to evaluate persistent VA. However, the following point needs to be considered: 1. In Material and Methods in paragraph concerning Duodenal sampling and assessment of histological findings the authors mentioned that "Immunohistochemistry was used for identification of intraepithelial lymphocytes (CD3 and CD8 expression), macrophages (CD68 expression), and plasmocytes (CD138 expression) evaluation in the stroma." However, there is no description of immunohistochemical method used in this study and any results of evaluation above mentioned cells.



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54235

**Title:** Non-invasive prediction of persistent villous atrophy in celiac disease

**Reviewer’s code:** 02440884

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Professor

**Reviewer’s Country/Territory:** Germany

**Author’s Country/Territory:** Czech Republic

**Manuscript submission date:** 2020-01-16

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-03-27 13:29

**Reviewer performed review:** 2020-03-27 13:48

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

In the retrospective study sensitivity, specificity, and negative predictive value of aTTG and aDGP serology to predict persistent villous atrophy was investigated in 82 patients. The authors conclude that combination of bowel ultrasound examination and improved serology may achieve better accuracy. As a normative value the authors use histological examination of mucosal biopsies and the graduation system Marsh/ Oberhuber. Comments 1. Histology is used as the normative to judge serology and bowel ultrasound. This correlation should be more clearly given in the abstract and in the body of the manuscript. 2. Results; Page 7: Oberhuber instead of Obenhuber 3. Results; percentages should given 22.2% ; 37.2% ; 29,3% instead of 22,2%; 37,2%; 29,3% 4. Graphs for correlation of Marsh/ Oberhuber classes with serology and ultrasound could help to better visualize the association.



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54235

**Title:** Non-invasive prediction of persistent villous atrophy in celiac disease

**Reviewer's code:** 03260089

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Czech Republic

**Manuscript submission date:** 2020-01-16

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-03-29 09:00

**Reviewer performed review:** 2020-03-29 09:36

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

- Introduction. "Mucosal healing is a main endpoint of this therapy; however, this goal is achieved only in about 60% of patients after one year of GFD" Define what do you mean for mucosal healing, since in many patients Marsh I damage persist, but this is not considered a problem - Do you advice to look for VA (invasively or not invasively) only in symptomatic patients or in asymptomatic patients too? If the second case, with what time-point? - "In our retrospective cohort study, we included patients who had been on the GFD for at least one year and for whom data on follow-up duodenal biopsy and quantitative evaluation of aTTG and/or aDGP using the enzyme-linked immunosorbent assay (ELISA) method was available as well." Why some of your patients (and others no) underwent to biopsy-follow up? - "Abdominal ultrasonography was available in subgroup of the patients." Why some of your patients underwent to ultrasonography follow-up examination? - "All the selected patients underwent esophagogastrosocopy with biopsy from the distal duodenum" Do you perform duodenal biopsied in DIII-DIV? - Statistical analysis Declare the statistically significant level you used. Specify the software. - Table 1: do not report mean and median, report one of two according to statistical distribution - "The most frequent clinical symptoms and laboratory signs of malnutrition at the time of follow-up biopsy were diarrhea (23.2%), abdominal pain (20.7%), weight loss (9.8%), sideropenia (26.8%), vitamin D deficiency (20.7%), and anemia (11.0%)." In clinical practice, the majority of CD patients respond well to GFD: how do you explain these number? - "However, non-invasive abdominal ultrasound is widely available" Abdominal ultrasound is widely available, but bowel ultrasound, at least in the majority of the country, is performed by only few specialists



### PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 54235

**Title:** Non-invasive prediction of persistent villous atrophy in celiac disease

**Reviewer's code:** 02535507

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Adjunct Professor, Associate Professor, Senior Scientist

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** Czech Republic

**Manuscript submission date:** 2020-01-16

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-03-29 11:20

**Reviewer performed review:** 2020-04-01 08:41

**Review time:** 2 Days and 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

This paper has the aim of finding markers which are predictive of villous atrophy in patients affected by celiac disease in treatment with gluten free diet. The conclusions are that a combination of anti-transglutaminase and anti-gliadin antibodies evaluated by an appropriate cut-off value with ultrasonographic intestinal picture may reach an optimal value of sensitivity and specificity. Main comments are: • Was villous atrophy that Authors found in these patients expression of a lack of response to gluten free diet or of gluten assumption? This aspect is relevant since encloses the real clinical purpose of this study. • “the study protocol was approved by the local ethical committee University Hospital Brno”, more specific details are requested. • “Lab kits for analyses were provided by TestLine Clinical Diagnostics ltd”. The location of the manufacturer is lacking. This is arelevant aspect expecially because it indicates the population who was tested for cut-off value validation. • Ultrasonographic aspects were referred only to a report of literature. Is it enough? • “The calculated cut-off values were 13.4 U/ml and 6.7”. How did they differ from that suggested by the manufacturer? How Authors explain this difference (if there is)? Could an “in situ validation” be useful?